Olinvyk (oliceridine)
/ Trevena, Jiangsu NHWA Pharma, Pharmbio
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
601
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
September 16, 2026
Observation of Oliceridine Fumarate in Burn Patients
(ChiCTR)
- P=N/A | N=60 | Not yet recruiting | Sponsor: Heze Municipal Hospital; Heze Municipal Hospital
New trial
September 20, 2026
Median effective dose and 95% effective dose of oliceridine combined with ciprofol for painless gastroscopy: a dose-finding study based on Dixon's up-and-down method.
(PubMed, Front Pharmacol)
- "There were no significant differences in the incidence of adverse events between the two sexes. For day-case painless gastroscopy, the ED50 of oliceridine combined with ciprofol (0.4 mg/kg) was 12.74 μg/kg in females and 17.37 μg/kg in males, with ED95 estimates of 17.69 μg/kg and 20.98 μg/kg, respectively."
Journal • Anesthesia • Pain
September 16, 2026
Study on the minimum effective dose of Oliceridine in PCIA combined with iliofascial block block for analgesia after knee arthroplasty
(ChiCTR)
- P=N/A | N=68 | Completed | Sponsor: The Second Hospital of Sanming city; The Second Hospital of Sanming
New trial • Musculoskeletal Diseases • Orthopedics
September 16, 2026
A Study of Suitable Oliceridine-Ciprofol Dose Combinations for Sedation During Gastroscopy in Older Adults
(ChiCTR)
- P=N/A | N=130 | Not yet recruiting | Sponsor: Xuzhou Traditional Chinese Medicine Hospital; Xuzhou Traditional Chinese Medicine Hospital
New trial • Anesthesia • CNS Disorders • Depression • Mood Disorders • Psychiatry
September 16, 2026
Effect of a Propofol–Oliceridine Anesthetic Strategy with Preserved Spontaneous Breathing on Early Recovery Quality after Ureteroscopic Holmium Laser Lithotripsy
(ChiCTR)
- P=N/A | N=92 | Not yet recruiting | Sponsor: Cixi People’s Hospital; Cixi People’s Hospital
New trial • Anesthesia • Urolithiasis
September 16, 2026
Oliceridine Compared with Propofol for the Treatment of Emergence Agitation in Adults Following General Anesthesia: A Randomized Controlled Trial
(ChiCTR)
- P=N/A | N=134 | Not yet recruiting | Sponsor: The First People's Hospital of Tianshui; The First People's Hospital of Tianshui
New trial • Anesthesia
September 16, 2026
Application of Oliceridine Combined with Ciprofol in Painless Gastrointestinal Endoscopy: A Randomized Controlled Trial
(ChiCTR)
- P=N/A | N=214 | Not yet recruiting | Sponsor: Liuzhou people's hospital; Liuzhou people's hospital
New trial • Gastroenterology • Gastrointestinal Disorder
September 16, 2026
Comparative Study on the Efficacy and Safety of Two Analgesic Regimens in ERCP Procedures
(ChiCTR)
- P=N/A | N=170 | Not yet recruiting | Sponsor: Hangzhou First People's Hospital; Hangzhou First People's Hospital
New trial • CNS Disorders • Depression • Mood Disorders • Psychiatry
September 16, 2026
Comparative Efficacy of Oliceridine and Sufentanil in Laparoscopic Postoperative Analgesia: Impact on Pain Relief and Hyperalgesia
(ChiCTR)
- P=N/A | N=144 | Not yet recruiting | Sponsor: Jilin Provincial People's Hospital; Jilin Provincial People's Hospital
New trial • Pain
September 16, 2026
Effect of intravenous anesthesia with oliceridine on the quality of postoperative recovery in patients undergoing transurethral lithotomy
(ChiCTR)
- P4 | N=190 | Recruiting | Sponsor: Jiangmen Central Hospital; Jiangmen Central Hospital
New P4 trial • Allergy • Anesthesia • Cardiovascular • Hypertension • Hypotension
September 13, 2026
Oliceridine versus Hydromorphone for Postoperative Analgesia: Interpreting the PONV Signal and the Limitations of Resting Pain as a Primary Endpoint [Response to Letter].
(PubMed, Drug Des Devel Ther)
- No abstract available
Journal • Pain
September 04, 2026
Efficacy of different doses of oliceridine for Patient-Controlled Intravenous Analgesia in patients undergoing Total Laparoscopic Hysterectomy.
(PubMed, PLoS One)
- "Within the investigated PCA oliceridine dose range, the 0.35 mg/kg dose promotes early recovery in patients undergoing laparoscopic total hysterectomy through effective analgesia and reduced nausea, representing the best balance between efficacy and safety among the tested oliceridine-specific regimens."
Clinical • Journal • Anesthesia • Cough • Gynecology • Pain • Respiratory Diseases
August 29, 2026
Effect of Oliceridine Patient-Controlled Intravenous Analgesia on Postoperative Chronic Pain After Video-Assisted Thoracoscopic Lung Resection
(clinicaltrials.gov)
- P4 | N=320 | Recruiting | Sponsor: Tianjin Medical University General Hospital | Enrolling by invitation ➔ Recruiting
Enrollment status • Pain
September 02, 2026
Effect of vaginal delivery history on oliceridine ED₅₀ combined with propofol during painless hysteroscopy: a modified Dixon sequential study.
(PubMed, Front Med (Lausanne))
- P=N/A | "This finding suggests that a history of vaginal delivery may be a useful factor to consider when individualizing initial oliceridine dosing in this setting. ChiCTR2500095126 (https://www.chictr.org.cn)."
Clinical • Journal • Anesthesia • Gynecology • Pain
September 02, 2026
PBPK-Based Prediction of Oliceridine Exposure in Breast Milk and Relative Infant Dose During the First 24 h After Cesarean Delivery.
(PubMed, J Clin Pharmacol)
- "Morphine benchmarking assessed the physiological plausibility of the M/P extrapolation step, and a 4-24 h temporal sensitivity check examined the influence of the initial accumulation phase. The maximum corrected RID was 0.818% in the two-way scan and 1.235% under the prespecified high-exposure scenario. These findings provide a preliminary, assumption-bounded quantitative reference for modeled relative infant exposure under prespecified postoperative Day 1 extrapolation assumptions."
Journal • Addiction (Opioid and Alcohol) • Pain
September 02, 2026
Oliceridine versus Sufentanil for Postoperative Intravenous Analgesia in Patients Undergoing Abdominal Surgery in the AICU: A Double-Blind Non-Inferiority Trial.
(PubMed, Drug Des Devel Ther)
- "Regarding adverse events, the incidence of nausea in the Oliceridine group (9.6%) was significantly lower than that in the sufentanil group (24.1%) (P < 0.05); there were no differences in the incidence of other adverse events. Among patients undergoing abdominal surgery at the AICU, the use of Oliceridine for postoperative analgesia was non-inferior to sufentanil and was associated with a lower incidence of postoperative nausea."
Clinical • Journal • Anesthesia • Critical care • Pain
August 30, 2026
Oliceridine Versus Hydromorphone for Postoperative Analgesia: Interpreting the PONV Signal and the Limitations of Resting Pain as a Primary Endpoint [Letter].
(PubMed, Drug Des Devel Ther)
- No abstract available
Journal • Pain
August 27, 2026
Efficacy and safety of oliceridine versus sufentanil for patient-controlled intravenous analgesia following gynecological laparoscopic surgery: a randomized, double-blind, parallel-group trial.
(PubMed, Front Med (Lausanne))
- P=N/A | "For postoperative analgesia following gynecological laparoscopic surgery, oliceridine provides effective analgesia comparable to sufentanil while significantly reducing the risk of opioid-related PONV, demonstrating a favorable safety profile. http://www.chictr.org.cn/, ChiCTR2400089648."
Clinical • Journal • Cough • Dermatology • Pain • Pruritus • Respiratory Diseases
August 24, 2026
Contact-network rewiring landscape of opioid receptors: Activation, ligand discrimination, and G-protein coupling | Poster Board #D25
(ACS-Fall 2026)
- "Within MOR, seven agonists form a graded ligand-discrimination spectrum ranked by contact-network divergence from fentanyl: PZM21 (0.065) < morphine (0.077) < endomorphin (0.087) < SR-17018 (0.094) < beta-endorphin (0.099) < DAMGO (0.122) < oliceridine (0.124). A three-tier changed-contact ontology separates receptor-internal, receptor-ligand, and non-receptor/mixed contributions, enabling clean partitioning of receptor-core biology from partner-context effects. These results demonstrate that curated experimental structures already encode pharmacologically informative comparative phenotypes without requiring molecular dynamics simulation and establish a generalizable platform for contact-network analysis of structurally mature GPCR families."
August 25, 2026
A Thought on Interpreting Single-Center Findings in the Oliceridine PONV Trial.
(PubMed, J Invest Surg)
- No abstract available
Journal
July 03, 2026
PN302. Frontiers of Ambulatory Anesthesia: Transforming Care Through New Technologies, Medications, and Procedures (1 CME)
(ASA 2026)
- "Pharmacologic advances include novel agents and new applications of established medications like remimazolam, oliceridine, ciprofol, suzetrigine, and dexmedetomidine. These innovations collectively define the evolving landscape of ambulatory anesthesia, and its expanding role in modern perioperative anesthetic care. SessionLearningObjective1: Describe emerging technologies in ambulatory anesthesia, including AI-driven predictive analytics, machine learning, wearable monitoring systems, and other innovations for perioperative care.SessionLearningObjective2: Discuss how novel medications and new applications of established anesthetic agents may enhance safety, efficiency, and recovery for ambulatory anesthesia.SessionLearningObjective3: Identify expanding procedural frontiers for ambulatory anesthesia and the perioperative management strategies required to ensure patient safety."
Orthopedics
August 21, 2026
Determination of the median effective dose (ED₅₀) of oliceridine combined with propofol for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy.
(PubMed, Front Med (Lausanne))
- P=N/A | "The ED₅₀ of oliceridine combined with propofol (1.5 mg/kg) for inhibiting gastroscope insertion responses in adult patients undergoing painless gastroscopy is 19.33 μg/kg. ChiCTR2500105523."
Journal • Anesthesia • Pain
August 15, 2026
Effects of oliceridine-based patient-controlled intravenous administration on postoperative pain and hemodynamic stability in elderly patients undergoing laparoscopic surgery for colorectal cancer.
(PubMed, Am J Cancer Res)
- "Patients were divided into three groups according to the analgesic regimen: a control group (Group C, fentanyl PCIA), a low-dose oliceridine group (Group O1), and a high-dose oliceridine group (Group O2), each comprising 50 patients. The number of remedial analgesia administrations within 24 hours postoperatively (0.4±0.2 times) and total flurbiprofen axetil consumption (25.0±12.5 mg) were significantly lower in Group O2 than in Groups O1 and C (P<0.05). High-dose Oliceridine PCIA provided better analgesic effects for elderly Laparoscopic Colorectal Cancer Patients after surgery, effectively reduced inflammatory response, and maintained stable Hemodynamic and Respiratory Function."
Journal • Addiction (Opioid and Alcohol) • Anesthesia • Colorectal Cancer • Oncology • Pain • Solid Tumor
August 13, 2026
Interpreting Respiratory Safety in an Oliceridine Gastroscopy Trial [Letter].
(PubMed, Drug Des Devel Ther)
- No abstract available
Journal
August 13, 2026
Oliceridine-Propofol Dose for Gastroscope Insertion in Obese Patients
(clinicaltrials.gov)
- P4 | N=80 | Not yet recruiting | Sponsor: Lu Yi
New P4 trial • Genetic Disorders • Obesity
1 to 25
Of
601
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25